Abstract: Cabozantinib (XL184) is a potent, orally administered small-molecule multi-kinase inhibitor that has significantly altered the treatment landscape for advanced and metastatic renal cell carcinoma (mRCC). By simultaneously targeting VEGFR, MET, and AXL, cabozantinib effectively inhibits tumor angiogenesis while overcoming the primary resistance mechanisms associated with chronic use of earlier-generation VEGF-targeted therapies. Clinical data, notably from the phase III METEOR trial, demonstrate that cabozantinib provides superior progression-free survival, overall survival, and objective response rates compared to standard second-line therapies like everolimus. Furthermore, cabozantinib exhibits unique immunomodulatory properties within the tumor microenvironment, providing a strong rationale for combination with immune checkpoint inhibitors. Despite its robust efficacy, the clinical utility of cabozantinib is often limited by a high incidence of adverse events, including diarrhea, hypertension, fatigue, and palmar-plantar erythrodysesthesia, which frequently necessitate dose modifications. Future research is heavily focused on optimizing treatment sequencing and exploring synergistic combinations with immunotherapies to achieve durable responses in refractory mRCC.
1. Introduction
Renal cell carcinoma (RCC) is a heterogeneous disease that accounts for a significant portion of adult malignancies, with advanced or metastatic stages historically presenting high morbidity and mortality rates [1]. The pathogenesis of clear cell RCC is frequently driven by mutations in the VHL tumor suppressor gene, leading to the accumulation of hypoxia-inducible factor (HIF) and the subsequent unregulated activation of angiogenesis pathways, including vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) [1]. Consequently, anti-angiogenic agents, particularly VEGF-targeted tyrosine kinase inhibitors (TKIs) like sunitinib and pazopanib, became the mainstay of first-line therapy [1]. However, tumor resistance to these initial therapies is an inevitable clinical reality, necessitating the development of next-generation agents [1]. Cabozantinib (XL184) has emerged as a critical therapeutic option for advanced RCC, approved for use in patients who have progressed on prior anti-angiogenesis therapy, as well as a first-line treatment for patients with intermediate or poor-risk disease [1] [2].
2. Pharmacological Activity
Cabozantinib has demonstrated robust pharmacological efficacy in clinical trials for advanced RCC. Its approval for second-line use was largely driven by the landmark phase III METEOR trial, which compared cabozantinib to the mTOR inhibitor everolimus in 658 mRCC patients who had experienced disease progression after prior TKI therapy [1]. In this study, cabozantinib significantly reduced the rate of disease progression by 42% compared to everolimus. It achieved a superior median progression-free survival (mPFS) of 7.4 months versus 3.8 months for everolimus [1]. Furthermore, cabozantinib provided a clear overall survival (OS) advantage (21.4 months compared to 16.5 months) and a significantly higher objective response rate (ORR) of 21% versus 5% [1]. Beyond the refractory setting, cabozantinib has also shown potent activity as an initial therapy; a phase II multicenter study comparing it to sunitinib in the first-line setting revealed a 31% reduction in the median rate of progression or death for patients treated with cabozantinib [1].
3. Molecular Mechanism of Action
Cabozantinib is a multi-targeted TKI that suppresses tumor growth, metastasis, and angiogenesis by inhibiting a broad spectrum of receptor tyrosine kinases. Its primary targets include VEGFR (VEGFR1, VEGFR2, VEGFR3), the hepatocyte growth factor receptor (MET), and the "anexelekto" (AXL) receptor tyrosine kinase [1] [2] [8]. It also effectively inhibits RET, KIT, FLT3, TIE-2, and RON [1] [2]. The dual inhibition of MET and AXL alongside VEGFR is the cornerstone of cabozantinib's mechanism in mRCC. Chronic use of earlier VEGF inhibitors like sunitinib leads to the upregulation of MET and AXL, which act as compensatory escape mechanisms driving tumor resistance [1] [5]. High expression of MET and AXL in RCC cells correlates with poor prognosis; thus, cabozantinib's ability to block these specific targets allows it to overcome acquired resistance to standard anti-angiogenic therapies [1].
In addition to its direct anti-tumor and anti-angiogenic effects, cabozantinib exerts significant immunomodulatory effects within the tumor microenvironment (TME). By inhibiting the HGF/c-Met pathway, cabozantinib impairs the function and expansion of immunosuppressive cells, including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) [7]. This reduction in immunosuppressive factors is accompanied by an increased tumor infiltration of CD8+ T cells, thereby shifting the TME to a more immune-permissive state that enhances tumor cell recognition and sensitivity to immune-mediated lysis [7].
4. Structure-Activity Relationship (SAR)
While the provided literature does not detail the specific chemical structure modifications of cabozantinib, its structural design translates into a highly potent and distinct kinase inhibitor selectivity profile compared to other multi-kinase inhibitors such as lenvatinib, sorafenib, and regorafenib [2]. Cabozantinib exhibits exceptionally low half-maximal inhibitory concentrations (IC50), indicating high binding affinity and potency for its targets. Specifically, it inhibits VEGFR2 with an IC50 of 0.035 nmol/L, MET at 1.3 nmol/L, AXL at 7 nmol/L, KIT at 4.6 nmol/L, RET at 5.2 nmol/L, and FLT3 at 11.3 nmol/L [2]. This specific multi-target binding capacity at the receptor kinase domain allows cabozantinib to simultaneously disrupt primary angiogenesis and secondary resistance pathways [1] [2].
5. Current Limitations
The primary limitation of cabozantinib therapy is its substantial toxicity profile, which is characteristic of potent anti-angiogenic multi-targeted TKIs. In the METEOR trial, 68% of patients treated with cabozantinib experienced grade 3 or 4 adverse effects, and dose reductions were required in 60% of the study population [1]. The most frequently reported adverse events across all grades include diarrhea (85%), fatigue (65%), hypertension (52%), palmar-plantar erythrodysesthesia (hand-foot syndrome, 50%), decreased appetite (48%), and nausea (54%) [1]. These gastrointestinal and dermatological toxicities can severely impact a patient's quality of life and require aggressive, proactive management—such as the use of anti-diarrheal medications, antihypertensives, and topical treatments—to prevent treatment discontinuation [2]. Furthermore, despite the significant survival benefits provided by cabozantinib, complete responses to single-agent TKI therapy remain rare, and eventual disease progression continues to be a major clinical hurdle [1].
6. Future Perspectives
The future clinical development of cabozantinib is heavily focused on combination therapies, particularly integrating it with immune checkpoint inhibitors. Because cabozantinib successfully neutralizes immunosuppressive MDSCs and Tregs while boosting CD8+ T cell infiltration, it provides a strong biological rationale for synergistic use with anti-PD-1 and anti-PD-L1 antibodies [7]. Numerous ongoing clinical trials (e.g., COSMIC-021, COSMIC-312) are actively evaluating cabozantinib in combination with agents like atezolizumab and nivolumab across various advanced solid tumors, including RCC and hepatocellular carcinoma, to achieve deeper and more durable clinical responses [2] [7]. Additionally, as the armamentarium of approved drugs for mRCC expands, further research is required to determine the optimal sequencing of cabozantinib relative to other novel therapies (such as nivolumab monotherapy or lenvatinib combined with everolimus) to maximize long-term patient survival and manage cumulative toxicities [1].
